The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer

Japanese Journal of Clinical Oncology

Volumn 29, Issue 12, 1999, Pages 623-629

  Oyama, Nobuyuki ^a   Akino, Hironobu ^a   Suzuki, Yuji ^a   Kanamaru, Hiroshi ^a   Sadato, Norihiro ^a   Yonekura, Yoshiharu ^a   Okada, Kenichiro ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Cancer detection; FDG PET; Prostate cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; SCINTISCANNING;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033253147     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.12.623     Document Type: Article

References (26)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-90.
2. Stone NN, DeAntoni EP, Crawford ED, Prostate Cancer Education Council. Screening for prostate cancer by digital rectal examination and prostate-specific antigen: results of prostate cancer awareness week. Urology 1994;44:1989-92.
3. Pantronas NJ, Chiro GD, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
4. Rege S, Maass A, Chaiken L, Hoe CK, Lufkin R, Anzai Y, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-58.
5. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MRI imaging correlation. Radiology 1993;186:27-35.
6. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Korniblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
7. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhrat R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-32.
8. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
9. Effert PJ, Bares R, Handt S, Wolff JM, Bull D, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
10. Laubenbacher C, Hofer C, Avril N, Block T, Ziegler S, Herz M, et al. F-18 FDG PET for differentiation of local recurrent prostate cancer and scar. J Nucl Med 1995;36(Suppl 1):198.
11. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F- 18]fluoro-D-glucose. Radiology 1996;199:751-6.
12. Yeh SDJ, Imbriaco M, Garza D, Kalaigian H, Reddy D, Zhang JJ, et al. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by FDG-PET whole body scanning. J Nucl Med 1995;36(Suppl 1):198.
13. Hoh CK, Rosen PJ, Belldegrun A, Moon DH, Maddahi J, Phelps ME. Quantitative and whole body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate cancer. J Nucl Med 1996;37(Suppl 1):267.
14. Sobin LH, Wittekind Ch, editors. TNM Classification of Malignant Tumors, 5th ed. New York: Wiley-Liss 1997.
15. Harnacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carried-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
16. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of whole-body PET scanner. J Nucl Med 1994;35:1398-406.
17. Patlak C, Blasberg R, Fenstermacher J. Graphical evaluation of blood to brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
18. Gjedde A. High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 1981;36:1463-71.
19. Gleason DF, Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of carcinoma of the prostate in urologie pathology. In: Tannenbaum M, editor. The Prostate. Philadelphia: Lea & Febiger 1977:171-97.
20. Bostwick DG, Quian J, Bergstralh E, Dundore P, Dugan J, Myers RP, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996;155:1361-7.
21. Coetzee LJ, Layfield LJ, Hars V, Paulson DF. Proliferative index determination in prostate carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? J Urol 1997;157:214-8.
22. Keyes JW. SUV: standard uptake or silly useless value. J Nucl Med 1995;36:1836-9.
23. Konishi N, Hiasa Y, Tsuzuki T, Enomoto T, Miller GJ. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997;30:53-7.
24. Watanabe M, Fukutome K, Shiraishi T, Murata M, Kawamura J, Shimazaki J, et al. Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 1997;18:1355-8.
25. Biaglow JE, Cerniglia G, Tuttle S, Bakanauskas V, Stevens C, McKenna G. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. Biochem Biophys Res Commun 1997;235:739-42.
26. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type 2 hexokinase promoter contains functionally active response elements for the tumor suppressor. J Biol Chem 1997;272:22776-80.